ITGA2B and hepatocellular carcinoma: One particular case of a patient with suspected/very-early-stage HCC had around similar percentage of CD41+ platelets i.e. 81.4% that is in accordance with our results of early-stage HCC but, it showed reduced MFI i.e. 41, which is near to the MFI of CD41 expression in cirrhosis patients.